Shots:

• The P-III CLL14 Study involves assessing of Venclexta/Venclyxto + Gazyva/Gazyvar vs Gazyva/Gazyvaro + chlorambucil in 432 patients with previously untreated chronic lymphocytic leukemia (CLL)
• P-III CLL14 Study results: ORR (84.7% vs 71.3%); CR (49.5% vs 23.1%); patients receiving Venclexta/Venclyxto lived longer; disease progression @2yrs. (88.2% vs 64.1%); no new safety signals observed
• Venclexta/Venclyxto is a drug targeted for binding & inhibiting BCL-2 protein- further leads to apoptosis and has received 5 times FDA’s BT designation in combination or monothx with approval in 50+ countries. Roche and AbbVie collaborated to develop Venclexta/Venclyxto

Ref: Roche | Image: Roche